A b atract. Watanabe Heritable Hyperlipidemic (WHHL) rabbits, like humans with familial hypercholesterolemia, have a genetic defect in the low density lipoprotein (LDL) receptor. WHHL fibroblasts produce a low molecular weight precursor form of the receptor that is not glycosylated normally and is not transported to the cell surface at a normal rate. In the current studies, we have used a monoclonal antibody that reacts with the rabbit LDL receptor to extend these findings to intact rabbits. We have made the following observations: (a) In normal rabbits the liver and adrenal glands synthesize high molecular weight mature LDL receptors like those in fibroblasts. (b) In WHHL rabbits the adrenals express only the low molecular weight receptor precursor, and the liver expresses no detectable receptors. (c) When injected intravenously, the radioiodinated anti-LDL receptor monoclonal antibody is cleared from plasma 6-10-fold faster in normal than in WHHL rabbits, with specific uptake demonstrable in livers and adrenals of normal but not WHHL rabbits. The latter finding raises the general possibility that the total number of cell surface receptors expressed by an animal or human in vivo can be estimated by measuring the rate of clearance of an intravenously injected monoclonal antibody directed against the receptor of interest.
Introduction
The Watanabe Heritable Hyperlipidemic (WHHL)' rabbit is a useful animal counterpart of familial hypercholesterolemia (reviewed in reference 1). WHHL rabbits, like humans with familial hypercholesterolemia, have a mutation in the gene encoding the low density lipoprotein (LDL) receptor. Animals that are homozygous for this defect express <5% of the normal number of functional LDL receptors, as measured in cultured fibroblasts (2) , liver and adrenal membranes (3) , and isolated hepatocytes (4) . As a result, these animals catabolize plasma intermediate density lipoproteins (IDL) and LDL inefficiently, and the lipoproteins accumulate to high levels in plasma, which produces fulminant atherosclerosis. The consequences of the receptor defect in these homozygous animals are quite similar to the consequences in children with homozygous familial hypercholesterolemia (1) .
The mutation in WHHL rabbits has recently been characterized at the protein level in cultured rabbit fibroblasts (5) . The LDL receptor of normal rabbits (5) , like that of humans (6) , is initially synthesized as a precursor with an apparent molecular weight of 120,000, as determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis under sulfhydryl reducing conditions. Within 15-30 min, the apparent molecular weight of the receptor shifts to 160,000 on SDS gels, apparently owing to the elongation of O-linked oligosaccharide chains in a series of reactions that are believed to occur in the Golgi complex (7) . Soon thereafter, the receptor appears on the cell surface as a 160,000-D glycoprotein. In WHHL rabbits, as in certain patients with familial hypercholesterolemia (the 0. family), the LDL receptor precursor is synthesized as a normally appearing 120,000-D protein (5) . However, in contrast to the normal precursor, the precursor in the WHHL rabbits and in the 0. family is transported to the surface slowly and the oligosaccharide chains are modified at <10% of the normal rate (5) . As a result, most of the receptors remain inside the cell where they are unable to perform their normal functions.
The advantage of the WHHL rabbit lies in the use of these animals for whole-body experiments that are not possible in humans with familial hypercholesterolemia. Indeed, previous studies in these animals have shown that the slow fractional rate of catabolism of plasma LDL (1, 2, 8, 9) is due primarily to inefficient uptake of LDL in the liver and adrenal gland, the two organs that rely most heavily on LDL receptors for rapid LDL uptake (9) .
In the current studies we have prepared a mouse monoclonal antibody that reacts with the rabbit LDL receptor and have used this antibody to probe the expression of LDL receptors in intact rabbits. In particular, we show that the adrenal glands of WHHL rabbits, like WHHL fibroblasts in tissue culture, accumulate the low molecular weight precursor form of the receptor. We also show that the mutant LDL receptor is not detectable structurally in the liver of WHHL rabbits. Finally, we show that WHHL rabbits remove '25I-labeled anti-receptor monoclonal antibody from the circulation much more slowly than normal rabbits. This latter result raises the general possibility that the rate of catabolism of an '25I-labeled monoclonal antibody directed against a cell surface receptor can be used as (1, 3, 4, 6 -tetrachloro-3a,6a-diphenylglycoluril) from Pierce Chemical Co., Rockford, IL. All other materials were obtained from previously reported sources (5, 6, 10, 11) .
Rabbits. New Zealand white rabbits ("normal rabbits") were purchased from Hickory Hill Rabbitry (Flint, TX). Homozygous WHHL rabbits were raised in Dallas as described (3, 12) . Animals were fed Purina rabbit chow and were 3-5 mo old (2-3.5 kg of body weight) at the time of study.
Lipoproteins. Rabbit LDL (d = 1.019-1.050 g/ml) from normal animals and rabbit a-migrating very low density lipoproteins (,6-VLDL) from cholesterol-fed animals were isolated as described previously (3, 13) . Human LDL (d = 1.019-1.063 g/ml) was prepared from plasma of individual healthy subjects (14). Plasma cholesterol levels were measured by the cholesterol oxidase method (13) .
Cultured cells. Cultured fibroblasts from normal and WHHL rabbits were derived from explants of skin and grown in monolayer culture as previously described (5).
Monoclonal antibodies. Monoclonal antibodies were produced by modification (15) T-8642, Sigma Chemical Co.). The digested receptor (50 Mug for each injection) was injected intraperitoneally into mice on days 0, 14, and 91 after emulsification with an equal volume of either complete (day 0) or incomplete (days 14 and 91) Freund's adjuvant. The fusion of splenocytes with P3-X63-Ag8.653 mouse myeloma cells (17) was carried out on day 95. Of the 1,632 wells that received aliquots of the fusion mixture, 98 produced visible clusters of hybridomas. Of these 98 wells, eight produced antibodies that bound to the purified bovine LDL receptor as measured by a solid-phase indirect binding assay (15) . After cloning and subcloning, the media from these eight hybridomas were tested for recognition of the purified LDL receptor from rabbit adrenal glands (5) by a solid-phase indirect binding assay (15) and by immunoblotting after SDS-polyacrylamide gel electrophoresis as described below. One of the eight clones produced an antibody, designated IgG-9D9, that cross-reacted with the rabbit LDL receptor. The control monoclonal antibody IgG-A9, directed against hamster 3-hydroxy-3-methylglutaryl CoA reductase, was produced in mouse hybridomas as previously described (18) . IgG-9D9 and IgG-A9 were isolated from ascites fluid by chromatography on columns of protein A-Sepharose CL-4B (15) or on columns of goat anti-mouse IgG coupled to Sepharose CL-4B. Both antibodies contained heavy chains of the IgG-I subclass.
Radioiodination procedures. Lipoproteins were labeled with 121 with the iodine monochloride method (14) to specific activities of 1-5 X 105 cpm/Mig protein. For 125I-labeled human LDL and rabbit LDL, -3% of the radioactivity was in lipid, as determined by chloroform/ methanol extraction (14). The monoclonal antibodies, IgG-9D9 and IgG-A9, were radiolabeled with the Iodogen method (15) with '25I or "'I as indicated to specific activities of -1 X 106 cpm/Mg. Rabbit antimouse IgG antibody (IgG fraction) was radiolabeled with the chloramine T method (19) to specific activities of I X I0' cpm/pg protein.
SDS-gel electrophoresis. One-dimensional electrophoresis of 7% SDS-polyacrylamide slab gels was carried out in the absence of reducing agents as previously described (1 1). Gels were calibrated with the following molecular weight standards: myosin, 200,000; phosphorylase b, 97,000; bovine serum albumin, 68,000; and ovalbumin, 43,000.
Immunoblotting. Electrophoretic transfer of proteins from SDS slab gels to nitrocellulose paper, incubation of the nitrocellulose with antibodies, and autoradiography were carried out as described (20, 21) . The monoclonal antibodies, IgG-9D9 and IgG-A9, were used at a concentration of 10 jg/ml, and '251-labeled rabbit anti-mouse IgG antibody (IgG fraction) was used at a concentration of 0.5 pg/ml and a specific radioactivity of -1 X 10' cpm/Mug.
Ligand blotting. Proteins from SDS slab gels were transferred electrophoretically to nitrocellulose paper (1 1, 20) . The paper was then incubated for 1 h at 37°C in buffer A (11) with 125I-labeled human LDL (4 Mug protein/ml; -4 X 105 cpm/Mg protein), washed with buffer B (1 1), rinsed with buffer containing 50 mM Tris-chloride and 2 mM CaC12 at pH 8, dried, and subjected to autoradiography as described by Daniel et al. (I 1). Molecular weight calibration was carried out as described (20) .
Intravenous injection of 125I or "'I-labeled monoclonal antibodies and measurement of tissue content of 125Ij and 31I-radioactivity.
Normal and WHHL rabbits, matched for sex and body weight, were studied in the fed state. All animals were unanesthetized and were kept in restraining cages. The 125I-or '311-labeled monoclonal antibody was mixed with I ml of autologous rabbit plasma and injected into the marginal ear vein. Serial 1-2-ml blood samples were collected over radioactivity was determined by measurement of the radioactivity in a plasma sample obtained 5 min after injection. In pilot experiments we found that >97% of the radioactivity in plasma at all time points was precipitable with trichloroacetic acid, which implies that it represents undegraded antibody. In experiments in which tissues were obtained, immediately before termination of the experiment the animals were anesthetized and perfused through the portal vein in situ with a solution that contained 150 mM NaCI and I mM CaCl2 (22) . Various organs were then removed, weighed, and cut either into l-g pieces for assay of 125J or 3'I-radioactivity (liver, kidneys, and lungs) or counted directly as whole organs (adrenals and spleen) (13) .
Whole blood exchange. Male WHHL rabbits were anesthetized with xylazine and ketamine, and a polyethylene catheter was inserted in the internal jugular vein as described (8) . The animals were allowed to recover from surgery 24-48 h before they were studied. For each exchange, 35 ml of blood was removed from a nonfasted WHHL rabbit, and this was replaced with an equal volume of blood from a normal rabbit that had been fasted for 24 h. The donor blood was collected by heart puncture in a citrate/phosphate/dextrose anticoagulant solution. The exchange was repeated five times with an equilibration time of 3 min between exchanges. 2 h after the last exchange, the WHHL rabbits were injected with '25I-IgG-9D9 and its catabolism was measured. After 10 d, at a time when the plasma cholesterol levels had risen to their pretransfusion values, the same WHHL rabbits were reinjected with '25I-IgG-9D9 and its catabolism was again measured.
Results
Preparation of a monoclonal antibody that reacts with the rabbit LDL receptor. Our previous anti-LDL receptor monoclonal antibodies were directed against bovine and human LDL receptors (reference 15 and unpublished data). None of these antibodies cross-reacted with the rabbit LDL receptor. Immunization of mice with partially purified LDL receptors from the rabbit adrenal gland failed to produce a high affinity monoclonal antibody. Therefore, we used an alternate approach. The purified bovine adrenal LDL receptor was treated with trypsin, and the tryptic fragments were used to immunize mice. Hybridomas were prepared from the mouse spleens, and the clones were assayed for secretion of an antibody that would react with purified LDL receptors from rabbit adrenal gland. One clone, designated 9D9, produced an antibody with heavy chains of the IgG-l subclass that reacted with the rabbit adrenal LDL receptor. This antibody was designated IgG-9D9. Fig. 1 gg/ml streptomycin) that was supplemented with 10% (vol/vol) NuSerum (5). On day 2, the medium was replaced with 3 ml of fresh medium A with 10% Nu-Serum. On day 3, each monolayer was washed with 2 ml of Dulbecco's phosphate-buffered saline and then switched to medium A that was supplemented with 5 Ag/ml insulin, 5 Ag/ml transferrin, and 5 ng/ml selenium (ITS Premix) (5) and 10%
(vol/vol) newborn calf lipoprotein-deficient serum in the absence or presence of I sg/ml of 25-hydroxycholesterol plus 15 ,g/ml cholesterol. Fresh medium of the same composition was added on day 4. On day 5, each monolayer received ice-cold medium that contained 5% lipoprotein-deficient serum plus the indicated concentration of monoclonal '251-IgG-9D9 (739 cpm/ng). After incubation for 2 h at 4VC, the total radioactivity bound to the cells was determined (15) .
Each value represents the average of duplicate incubations.
normal rabbit fibroblasts internalized and degraded the antibody to trichloroacetic acid-soluble material in a receptor-dependent fashion (Table I) . After incubation with '23I-IgG-9D9 for 5 h, normal rabbit fibroblasts contained 607 ng of the antibody per milligram of cell protein and had degraded 398 ng/mg protein.
The WHHL fibroblasts took up and degraded <7% of the normal amount of the monoclonal antibody.
Detection of the LDL receptor after electrophoresis of adrenal and liver membrane proteins. Adrenal glands of normal and WHHL rabbits were homogenized, and a crude 100,000 g pellet of membranes was solubilized and subjected to electrophoresis in SDS-polyacrylamide gels in the absence of a sulfhydryl reducing agent. The proteins were transferred to nitrocellulose paper, which was incubated with monoclonal IgG-9D9 followed by an 1251I-labeled rabbit anti-mouse IgG.
Adrenal membranes from normal rabbits showed a major immunoreactive band at -130,000 D (Fig. 2) , which corresponds to the known migration of the mature LDL receptor in the absence of reducing agents (reference 11 and see Discussion). There was also a minor band at -90,000 D, which corresponds to the migration of the unprocessed receptor precursor under the same nonreducing conditions (reference 11 and see Discussion). The adrenal membranes from WHHL rabbits had no detectable 130,000-D mature receptor. However, these glands contained relatively large amounts of the 90,000-D material, which corresponds to the unprocessed precursor. These findings in adrenal homogenates were consistent with previous studies in cultured WHHL fibroblasts, which indicated that the mutant receptor produced by the WHHL rabbits is not processed to the mature form at a normal rate and therefore it remains predominantly in the precursor form (5) . IgG-9D9 also bound to the LDL receptor of normal rabbit liver (Fig. 3) . Because of the lower concentration of receptor in liver as compared with the adrenals, it was first necessary to partially purify the receptor by elution from a DEAEcellulose column. Fig. 3 A shows an immunoblot of an SDSpolyacrylamide gel of fractions eluted from such a column. Immunoreactive receptor emerged from the column in fractions 16 through 22, with a peak at fraction 18. When the same experiment was performed on extracts of WHHL liver membranes, no immunoreactive LDL receptor was seen (Fig. 3 B) .
The mature LDL receptor protein of normal rabbit liver that bound IgG-9D9 also bound human LDL. Fig. 4 A shows a ligand blot performed on fractions that were obtained from a DEAE-cellulose column of normal rabbit liver extracts, which were subjected to SDS-gel electrophoresis, transferred to nitrocellulose, and incubated with '251-LDL. The '25I-LDL bound to the mature receptor in fractions 15 through 24. No '251-LDL bound to the corresponding fractions from membranes of a WHHL rabbit liver (Fig. 4 B) .
Use ofmonoclonal '25I-IgG-9D9 turnover measurements to estimate the number of LDL receptors in vivo. When 12S1_ mM NaCl, and I mM phenylmethylsulfonylfluoride with 20 strokes of a loose-fitting pestle in a Dounce homogenizer. All operations were carried out at 0-4°C. The homogenates were spun at 100,000 g for I h, and the pellets were resuspended in buffer that contained 20 mM Tris-chloride (pH 8) and I mM phenylmethylsulfonyl fluoride by aspiration through a 22-gauge needle to a final protein concentration of 2 mg/ml. Triton X-100 was added to a final concentration of 1% (vol/vol). After incubation for 10 min at 4°C, insoluble material was removed by centrifugation at 100,000 g for 1 h. An equal volume of buffer that contained 20% (vol/vol) glycerol, 125 mM Tris-chloride (pH 6.8), and 4.6% (wt/vol) SDS was added to the supernatant, and the mixture was spun in a microfuge for 5 min. Aliquots (250 Ml) of the resulting supernatant were subjected to 7% SDS-gel electrophoresis with nonreducing conditions, electrophoretic transfer to nitrocellulose, and immunoblotting with IgG-9D9 (lanes I and 2) and IgG-A9 (lanes 3 and 4) as described in Methods. The nitrocellulose sheet was exposed to x-ray film for 24 h. M, standards are indicated.
labeled IgG-9D9 was administered intravenously to normal rabbits, the radioactivity was rapidly cleared from plasma, with 50% removed in 1-2 h (Fig. 5 A) . When the same radiolabeled antibody was administered to WHHL rabbits, the radioactivity was removed from the circulation much more slowly. By 6 h, <40% of the antibody had been removed from the circulation (Fig. 5 A) . IgG-A9, a control monoclonal IgG of the same subclass as IgG-9D9, was used to test the specificity of catabolism of '25I-IgG-9D9 in rabbits. IgG-A9 is directed against hamster 3-hydroxy-3-methylglutaryl CoA reductase, an intracellular enzyme that should not be accessible to the monoclonal immunoglobulin in the plasma. '25I-IgG-A9 disappeared slowly from the plasma in both normal and WHHL rabbits (Fig.  5 B) . Table II shows the distribution of radioactivity in various tissues of normal and WHHL rabbits 1 h after injection of a mixture of anti-receptor 1251-IgG-9D9 and control '3'I-IgG-A9. In the normal animals two tissues, liver and adrenal, took up 4-and 24-fold more '25I-IgG-9D9 than the control '31I-IgG-A9. In the WHHL rabbits there was no selective uptake of '251_IgG(9D9 in these two tissues (the ratios of uptake of 1251I IgG-9D9 to '3'I-IgG-A9 in these tissues in WHHL rabbits were 0.5 and 1.0, respectively). These findings suggest that the rapid uptake of the '251-IgG-9D9 in normal liver and adrenal glands is mediated by the LDL receptor. Figure 3 . Immunoblotting of LDL receptors from the liver of normal (A) and WHHL (B) rabbits. Livers were perfused in situ with a solution that contained 150 mM NaCl and 1 mM CaCI2 via the portal vein for 3 min (12) and immediately placed in ice-cold buffer that contained 20 mM Tris-chloride (pH 8), 1 mM CaC12, 150 mM NaCl, and I mM phenylmethylsulfonylfluoride. Membrane pellets from 70 g (wet weight) of each liver were prepared (30) , and solubilized with detergent as described (10) , except that 20 mM CHAPS was used instead of 1% (vol/vol) Triton X-100. DEAE-cellulose chromatography of each of the two detergent extracts (610 mg protein in each extract) was carried out on identical columns as previously described (10) except that 20 mM CHAPS was substituted for 1% Triton X-100. The columns were eluted with an 80-ml linear gradient of 0-350 mM NaCI in buffer that contained 50 mM Trismaleate (pH 6), 2 mM CaC12, and 40 mM octylglucoside. Fractions of 3.2 ml were each collected, and 70 Al of corresponding fractions from the normal rabbit (A) and the WHHL rabbit (B) were subjected to electrophoresis on 7% SDS slab gels with nonreducing conditions, followed by transfer to nitrocellulose paper, and immunoblotting with IgG-9D9 and '25I-labeled rabbit anti-mouse IgG, as described in Methods. The nitrocellulose paper was exposed to x-ray film for 24 h. Mr standards are indicated.
kidneys showed no selective uptake of 123I-IgG-9D9 in either normal or WHHL animals.
The slow clearance from plasma and sluggish tissue uptake of 25I-IgG-9D9 in the WHHL rabbit can be attributed to a deficiency of LDL receptors in the liver and adrenal of these animals. However, it is also possible, theoretically at least, that LDL receptors might be expressed in WHHL (Fig. 6 A) . Unlabeled IgG-9D9 showed a slight amount of competition, which reached a maximum of -30%.
The control IgG-A9 gave no competition. Fig. 6 (Fig. 6 B) . This inhibition by EDTA can be completely reversed by excess Ca", which indicates that binding of '25 -IgG-9D9 to the LDL receptor has an absolute requirement for divalent cation (data not shown), just as has been observed with the ligands LDL and fl-VLDL (Fig. 6 A and reference 3) .
To further explore the possibility of lipoprotein competition for '25 -IgG-9D9 binding in vivo, we measured the disappearance of intravenously administered '25 -IgG-9D9 before and after the infusion of an extremely large dose of fl-VLDL to normal rabbits. Fig. 7 shows that '23I-IgG-9D9 was removed rapidly from the blood of normal rabbits. When the rabbits were given sufficient fl-VLDL to raise their total plasma cholesterol levels from 26 and 45 mg/dl to 759 and 869 mg/ dl, the removal of 125 -IgG-9D9 was slowed somewhat, but the removal rate was still much faster than that of the control monoclonal 125I-IgG-A9 (Fig. 7 B) . Prior injection of unlabeled f,-VLDL had no effect on the removal of the control IgG (Fig.  7 B) . These data suggest that extremely high levels of a potential competing ligand are not able to abolish the receptormediated removal of 125 -IgG-9D9 from plasma of normal rabbits. To further test the possibility that the high levels of circulating endogenous lipoproteins were competing for removal of 1251-IgG-9D9 in WHHL rabbits, we removed aliquots of blood from the WHHL rabbits and replaced them with equal volumes of blood from normal rabbits, thereby lowering the cholesterol level in the WHHL rabbit. The clearance of intravenously administered '251-IgG-9D9 was measured in each animal before and after such blood exchange (Fig. 8) In previous studies of cultured fibroblasts, we found that the cells from WHHL rabbits synthesize a low molecular weight receptor precursor that resembles the precursor synthesized by normal rabbit fibroblasts (5). However, in WHHL rabbits the precursor is processed to the mature high molecular weight form at an abnormally slow rate (5). The low molecular weight precursor of the LDL receptor in human and rabbit cells migrates on SDS gels with a mobility corresponding to an apparent molecular weight of 120,000 when electrophoresis is performed in the presence of sulfhydryl reducing agents (5-7). Under these conditions, the apparent molecular weight of the processed mature receptor is 160,000 (5-7). In the absence of reducing agents, the precursor of the human LDL receptor migrates with an apparent molecular weight of 90,000 and the mature form shows an apparent molecular weight of 130,000 Table I Two normal and two WHHL females were each injected with a mixture of '251I-IgG-9D9 (4.7 X 107 cpm) and '3'I-IgG-A9 (1.3 X 10' cpm). After I h, animals were killed and the 23I-and '3'I-radioactivity in the indicated tissues were measured by double-label scintillation counting.
The results are expressed as percent of injected dose per gram of tissue, which is equal to (counts per minute per gram tissue divided by the counts per minute injected) X 102. Each value represents the data from one animal. * The (a)/(b) ratio represents the mean ratio of IgG-9D9 uptake to IgG-A9 uptake in the organs of the two animals. Binding of '25I-labeled ligands to partially purified LDL receptors was measured by the standard filtration assay as previously described (27) . Each assay tube (100 ;l) contained 35 Mg of phosphatidylcholine/acetone-precipitated receptor protein (27) , and incubations were carried out for 60 min at 240C with either rabbit '251I-LDL ( (11). Our current ligand blotting and immunoblotting techniques can be used only when SDS-gel electrophoresis is performed in the absence of reducing agents (1 1, 20) . Under these conditions the rabbit adrenal LDL receptor precursor has an apparent molecular weight of 90,000 and the mature form corresponds to a molecular weight of 130,000 (Fig. 2) as in human cells (1 1) . The current studies show that the low molecular weight receptor precursor accumulates in the adrenal glands of intact WHHL rabbits. Such accumulation is presumably due to the large demand for cholesterol for steroid hormone synthesis in the adrenal, which leads to the synthesis of large numbers of LDL receptors. In normal liver, the amount of LDL receptor activity per gram of tissue is only about one-tenth the amount present per gram of adrenal tissue (25) . For this reason, we were unable to obtain definitive immunoblots after electrophoresis of crude liver membranes. Therefore, we had to partially purify the receptor by DEAE-cellulose chromatography before immunoblotting. With this procedure it was possible to visualize the mature high molecular weight LDL receptor in extracts of normal liver. We were not able to visualize any immunoreactive receptor in the WHHL liver extracts that were prepared in an identical fashion. The failure to observe a receptor precursor in WHHL liver might be due to a failure of the precursor to be solubilized by the current procedure, or to a different behavior of the precursor during DEAE-cellulose chromatography. The precursor has a much lower negative charge than the mature receptor because of its lack of sialic acid (7). Therefore, it might be expected to behave differently upon solubimization and DEAE cellulose chromatography. If a precursor does accumulate in the livers of WHHL rabbits, its demonstration will require further refinements of currently available analytical techniques.
The use of a radiolabeled monoclonal antibody plasma decay curve to estimate the number of receptors in vivo is of potential general importance. The usefulness of'25f-IgG-9D9 depends on a property of the LDL receptor known as receptor recycling. Previous studies in cultured fibroblasts have shown that the LDL receptor cycles in and out of cells about once every 10 mma (26) . If a monoclonal antibody is bound to the receptor, it moves into the cell with the receptor and is deposited in an endosome, which is the site at which the LDL dissociates from the receptor. The receptor then returns to the surface to bind a new molecule of LDL and antibody. The '25I-IgG-9D9 that is deposited in endosomes is eventually (27) . In normal rabbits, the anti-LDL receptor monoclonal antibody was removed from the plasma several times more rapidly (half-life, 1.5 h) than a control IgG of the same subclass. The anti-receptor antibody also disappeared more rapidly than native LDL (half-life, -6 h) (8) The rapid disappearance of '25I-IgG-9D9 in normal rabbits was due primarily to rapid uptake into the liver. At 1 h the liver had taken up '30% of the total administered dose of '25I-IgG-9D9, which represented 80% of the total amount of IgG-9D9 that had disappeared from the plasma at this time point (Table II and Fig. 5 ). In contrast, at 1 h the liver contained only 7% of the total administered dose of the control antibody, '311-IgG-A9. Although the adrenal glands showed the highest relative amount of receptor-mediated uptake of 125I-IgG-9D9 (24-fold greater uptake than that of control '3'IIgG-A9), the total contribution of the adrenals to overall 1251_ IgG-9D9 clearance is small. The failure to find significant uptake of '25I-IgG-9D9 in the other tissues does not necessarily indicate an absence of functional LDL receptors in these tissues. The background in this type of assay is relatively high, i.e., relatively large amounts of the control '31I-IgG-A9 accumulate in extracellular spaces. Therefore, it would be easy to miss a significant amount of specific receptor-mediated intracellular uptake of the '25I-IgG-9D9 on the basis of a 1 h-time point.
It should also be noted that the tissue content of 125I1 radioactivity might represent a slight underestimate of LDL receptors since some of the '251-radioactivity derived from degraded '25I-IgG-9D9 might have left the cell, even at the 1-h time point. In this regard, it may be useful in future studies to label the monoclonal antibody with radioactive sucrose or tyramine cellobiose, which remain trapped in lysosomes after receptor-mediated endocytosis (28, 29).
In addition to its more rapid removal than LDL, the radioactive monoclonal anti-receptor antibody has another advantage over 125I-LDL for plasma turnover studies. This advantage stems from the observation that binding of '25IIgG_ 9D9 to the LDL receptor is inhibited only slightly by a marked excess of LDL or j-VLDL. One of the problems encountered in studying regulation of LDL receptors at the whole-animal level is in the area of competition between the administered tracer dose of radiolabeled lipoprotein and the endogenous unlabeled lipoproteins. For example, when rabbits were fed cholesterol, their ability to clear '25I-f-VLDL from the plasma diminished markedly (13) . Part of this decrease was attributed to a suppression of hepatic LDL receptors, as determined by direct assays of '25I-fl-VLDL binding to liver membranes. Part of the decrease in clearance was also due to excessive plasma levels of unlabeled f-VLDL, which competed with the 125-1-VLDL for receptor occupancy (13) . As a result, we were not able to conclude from the turnover studies alone that there was a suppression of LDL receptors after cholesterol feeding. 
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Many receptors, in addition to the LDL receptor, promote the uptake of their ligands through receptor-mediated endocytosis (26) . Therefore, it should be possible to use plasma disappearance curves of monoclonal antibodies that are tagged with radioactivity or other markers to measure the relative number of these receptors at a whole-body level. If binding of the monoclonal antibodies is not competitively inhibited by the endogenous ligand and if these antibodies do not block receptor recycling, these antibodies can be used to assess the number of functioning receptors even when circulating ligand levels are high. If administration of tracer amounts of monoclonal antibodies to man is shown to be safe, one could use such monoclonal antibodies for diagnostic purposes in measuring either genetic or acquired regulatory defects in receptors, such as the reduction of insulin receptors in diabetes and the reduction of LDL receptors in humans with either genetic defects or on high cholesterol diets.
